<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="672">
  <stage>Registered</stage>
  <submitdate>31/08/2005</submitdate>
  <approvaldate>31/08/2005</approvaldate>
  <nctid>NCT00143026</nctid>
  <trial_identification>
    <studytitle>Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States</studytitle>
    <scientifictitle>Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CELC200A2406</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Parkinson's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - carbidopa, levodopa, entacapone

Treatment: drugs: carbidopa, levodopa, entacapone


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Quality of life assessment</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom control change from baseline</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in number of wearing-off symptoms</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in proportion of patients experiencing wearing-off</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3
             symptoms

          -  Motor functions must be regarded as non-disabling by the patient</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History, signs or symptoms suggesting the diagnosis of atypical or secondary
             parkinsonism

          -  History of dyskinesia

          -  Previous or current use of entacapone or tolcapone

          -  Unstable Parkinson's disease patients requiring/receiving regimens of levodopa

          -  Subjects taking levodopa/DDCI controlled release or extended release formulations</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>184</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Watkins Medical Center - Brisbane</hospital>
    <hospital>Central Coast Neuroscience Research - Gosford</hospital>
    <hospital>Heidelberg Repatriation Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <hospital>Concord Hospital - Sydney</hospital>
    <hospital>Southern Neurology, St. George Private Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Gosford</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Linkou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bankok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study examines the effect of treatment of levodopa/entacapone on quality of life, as
      measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients
      with no or minimal, non-disabling motor fluctuations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00143026</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>